SMARCA4 and neoplasm: In fact, the only cells previously known to deficient for both BRG1 and BRM are certain tumor-derived cell lines [2], [5], and these tumor cells may have subverted the normal requirement for at least one catalytic subunit via inhibition of apoptosis.